← Back to patent-cliff list
[F-18]Flornaptitril
Tier C — Watch / trade[F-18]Flornaptitril
University of California, Los Angeles (UCLA)
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Radiopharmaceutical
Type
Targets：APP, TAU
Indications (approved)：Alzheimer's disease, 慢性创伤性脑病
Regional status
US
Phase III
2025-07-01
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of [F-18]Flornaptitril?
Approved indications include: Alzheimer's disease, 慢性创伤性脑病.
When does the [F-18]Flornaptitril patent expire?
No public expiry year is available for [F-18]Flornaptitril yet; this page updates once verified.
How do I get a quote for [F-18]Flornaptitril intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30